Residency · Residency · Nephrology

Metabolic Acidosis - Anion Gap and Non-Anion Gap

Introduction

Metabolic acidosis is defined by a primary decrease in serum bicarbonate concentration, with a secondary compensatory decrease in PaCO2 as predicted by Winter's formula. The fundamental classification divides metabolic acidosis into anion gap (AG) metabolic acidosis, caused by the addition of an acid with an unmeasured anion, and non-anion gap (hyperchloremic) metabolic acidosis, caused by the loss of bicarbonate or failure to regenerate bicarbonate, with chloride replacing bicarbonate to maintain electroneutrality. This distinction has profound diagnostic and therapeutic implications, as the differential diagnosis and management differ substantially between these two categories.

Anion Gap Metabolic Acidosis

Mnemonic: GOLDMARK (updated from MUDPILES)

The GOLDMARK mnemonic provides an updated and more clinically relevant framework for the differential diagnosis of anion gap metabolic acidosis. G represents glycolysis products, specifically D-lactic acidosis, which results from bacterial production of D-lactate in patients with short bowel syndrome. O represents oxoproline (5-oxoproline or pyroglutamic acid), a condition associated with chronic acetaminophen use in the setting of glutathione depletion, malnutrition, or sepsis. L represents lactic acidosis, the most common cause in hospitalized patients. D represents diabetic ketoacidosis and other ketoacidoses. M represents methanol poisoning. A represents aspirin (salicylate) toxicity. R represents renal failure (uremia). K represents ketoacidosis, encompassing starvation and alcoholic ketoacidosis.

Lactic Acidosis

Lactic acidosis is subdivided into type A and type B based on the presence or absence of tissue hypoxia. Type A lactic acidosis, resulting from tissue hypoxia or hypoperfusion, is the most common cause of anion gap metabolic acidosis in hospitalized patients. It occurs in cardiogenic, septic, and hypovolemic shock, severe anemia, carbon monoxide poisoning, and mesenteric ischemia. A serum lactate level exceeding 4 mmol/L in the setting of sepsis is associated with mortality rates exceeding 30 percent.

Type B lactic acidosis occurs without evidence of tissue hypoperfusion and is subdivided into three categories. Type B1 results from underlying diseases including hepatic failure, which impairs lactate clearance; malignancy, where tumor cells preferentially use anaerobic glycolysis even in the presence of oxygen (the Warburg effect); thiamine deficiency, which impairs pyruvate dehydrogenase function; and seizures, which generate lactic acid from intense muscular activity. Type B2 results from drugs and toxins including metformin, which inhibits mitochondrial complex I; linezolid, which impairs mitochondrial protein synthesis; propofol in propofol infusion syndrome; nucleoside reverse transcriptase inhibitors, which cause mitochondrial toxicity; and high-dose epinephrine and albuterol. Type B3 encompasses inborn errors of metabolism including mitochondrial myopathies and pyruvate dehydrogenase deficiency.

D-lactic acidosis is a unique entity produced by colonic bacteria in patients with short bowel syndrome and is not measured by the standard L-lactate assay used in most clinical laboratories. Patients present with encephalopathy and ataxia in the setting of an unexplained anion gap metabolic acidosis.

Diabetic Ketoacidosis (DKA)

Diabetic ketoacidosis results from absolute or relative insulin deficiency, which leads to unrestricted lipolysis and hepatic ketogenesis. The ketone bodies produced, in order of concentration, are beta-hydroxybutyrate (the predominant ketoacid), acetoacetate, and acetone. The diagnostic criteria include pH less than 7.30, bicarbonate less than 18 mEq/L, anion gap greater than 12, and serum glucose typically exceeding 250 mg/dL, though euglycemic DKA occurring in patients on SGLT2 inhibitors may present with glucose levels below 250 mg/dL. The beta-hydroxybutyrate to acetoacetate ratio, normally approximately 1:1, increases to as high as 10:1 in DKA. The nitroprusside test for urine ketones detects only acetoacetate and not beta-hydroxybutyrate, which can lead to falsely negative results early in DKA when beta-hydroxybutyrate predominates, and paradoxically positive results during treatment as beta-hydroxybutyrate is converted to acetoacetate. Point-of-care beta-hydroxybutyrate measurement exceeding 3.0 mmol/L is diagnostic and avoids these pitfalls.

Toxic Alcohol Ingestions

Methanol is metabolized to formic acid, which is directly toxic to the retina and basal ganglia, potentially causing blindness and neurologic devastation. Early in methanol poisoning, the osmol gap is elevated while the anion gap may be normal; as methanol is metabolized to formic acid, the osmol gap falls and the anion gap rises. Treatment consists of fomepizole at a loading dose of 15 mg/kg, which inhibits alcohol dehydrogenase and prevents metabolism to toxic metabolites, along with hemodialysis for severe cases with pH less than 7.15, visual symptoms, renal failure, or methanol levels exceeding 50 mg/dL.

Ethylene glycol is metabolized to glycolic acid and oxalic acid, the latter forming calcium oxalate crystals that deposit in the kidneys, causing acute kidney injury. Urinalysis may reveal characteristic envelope-shaped calcium oxalate monohydrate and needle-shaped dihydrate crystals. Treatment parallels that of methanol, with fomepizole and hemodialysis. The osmol gap, calculated as the difference between measured and calculated osmolality (using the formula 2 times sodium plus glucose divided by 18 plus BUN divided by 2.8), exceeds 10 mOsm/kg when unmeasured osmoles are present. Importantly, the osmol gap and anion gap evolve inversely over time as the parent compound is metabolized to its acid metabolites.

Uremic Acidosis

As GFR declines below 20 to 30 mL/min, the kidneys' ability to excrete ammonium becomes impaired, leading to retention of sulfuric acid, phosphoric acid, hippuric acid, and other organic acids. Initially, the acidosis is non-anion gap in character because reduced ammonium excretion occurs with intact chloride handling. As renal function deteriorates further and unmeasured anions accumulate, the acidosis transitions to an anion gap pattern. Treatment with oral sodium bicarbonate to maintain serum bicarbonate above 22 mEq/L has been shown in the UBI trial to slow CKD progression.

<image>Diagnostic flowchart for anion gap metabolic acidosis. Start with calculation of the albumin-corrected anion gap. If AG is elevated (>14 mEq/L), branch into the major categories: check lactate (if elevated, differentiate Type A vs Type B lactic acidosis), check ketones/beta-hydroxybutyrate (DKA, AKA, starvation), check osmol gap (if elevated, consider methanol or ethylene glycol and show the timeline of osmol gap falling as AG rises), check BUN/creatinine (uremic acidosis), check salicylate level, and consider rare causes (D-lactic acidosis, 5-oxoproline). Include delta-delta ratio calculation at the bottom to assess for concurrent non-AG acidosis or metabolic alkalosis.</image>

Non-Anion Gap (Hyperchloremic) Metabolic Acidosis

Pathophysiology

Non-anion gap metabolic acidosis results from either the loss of bicarbonate through the gastrointestinal tract or kidneys, or the failure to excrete the daily fixed acid load. When bicarbonate is lost, chloride concentration rises to maintain electroneutrality, producing the characteristic hyperchloremic pattern. Serum chloride is elevated relative to sodium concentration.

Urine Anion Gap (UAG)

The urine anion gap, calculated as the sum of urine sodium and urine potassium minus urine chloride, serves as an indirect estimate of urinary ammonium excretion. Ammonium is the unmeasured cation in urine, so when ammonium excretion is appropriately increased, the measured cations (sodium plus potassium) are less than the measured anion (chloride), producing a negative UAG. A negative UAG indicates appropriate renal ammonium excretion and suggests gastrointestinal bicarbonate loss, typically from diarrhea. A positive UAG indicates impaired renal ammonium excretion and suggests renal tubular acidosis. The UAG is unreliable in the presence of ketonuria, glycosuria, or severe volume depletion with very low urine sodium.

Urine Osmol Gap

The urine osmol gap, calculated as the difference between measured urine osmolality and calculated urine osmolality (using the formula 2 times the sum of urine sodium and urine potassium, plus urine urea divided by 2.8, plus urine glucose divided by 18), provides a more accurate estimate of urinary ammonium excretion than the UAG. A urine osmol gap exceeding 400 mOsm/kg indicates appropriate ammonium excretion and points to gastrointestinal bicarbonate loss. A urine osmol gap less than 150 mOsm/kg indicates impaired ammonium excretion and suggests renal tubular acidosis.

GI Bicarbonate Loss

Diarrhea is the most common cause of non-anion gap metabolic acidosis, as stool contains bicarbonate at concentrations of 30 to 50 mEq/L. Other gastrointestinal causes include pancreatic or biliary drainage and fistulae. Ureteral diversions such as ileal conduits and ureterosigmoidostomy cause non-anion gap metabolic acidosis because the colonic or ileal mucosa secretes bicarbonate in exchange for chloride when exposed to urine. Cholestyramine can cause hyperchloremic acidosis by exchanging chloride for bicarbonate in the intestinal lumen.

Renal Tubular Acidosis (RTA)

Type 1 (Distal) RTA

Type 1 RTA results from a defect in hydrogen ion secretion by type A intercalated cells in the collecting duct. The defining characteristic is the inability to acidify urine below pH 5.5 despite systemic acidosis. Serum bicarbonate can fall to very low levels, often below 10 mEq/L, because the collecting duct cannot trap ammonia as ammonium for excretion. The disorder is associated with hypokalemia from obligatory potassium wasting, nephrocalcinosis, nephrolithiasis with calcium phosphate stones that form in the persistently alkaline urine, and metabolic bone disease. Etiologies include Sjogren syndrome, systemic lupus erythematosus, amphotericin B, lithium, toluene exposure, medullary sponge kidney, and hereditary forms caused by mutations in the H-ATPase or the anion exchanger AE1. Treatment involves alkali supplementation with sodium bicarbonate or sodium citrate at 1 to 2 mEq/kg per day.

Type 2 (Proximal) RTA

Type 2 RTA results from a defect in proximal bicarbonate reabsorption, either through reduced NHE3 or NBCe1 function. The bicarbonate threshold is reduced from the normal 24 to approximately 15 to 18 mEq/L. Once serum bicarbonate falls below this threshold, the remaining distal nephron can handle the reduced filtered load and urine acidification is intact, producing a urine pH below 5.5. Proximal RTA is frequently part of the Fanconi syndrome, which includes glucosuria, aminoaciduria, phosphaturia, uricosuria, and low-molecular-weight proteinuria. Causes include multiple myeloma with light chain deposition, carbonic anhydrase inhibitors such as acetazolamide and topiramate, ifosfamide, tenofovir disoproxil fumarate, heavy metals, Wilson disease, and hereditary forms with NBC1 mutations. Treatment requires large doses of sodium bicarbonate, often 10 to 15 mEq/kg per day, which is difficult to maintain because the excess bicarbonate is rapidly excreted in the urine. Thiazide diuretics may reduce bicarbonate requirements by inducing mild volume contraction that enhances proximal reabsorption. Hypokalemia is a common complication because bicarbonate delivery to the distal nephron acts as a non-reabsorbable anion, increasing lumen negativity and driving potassium secretion.

Type 4 RTA (Hypoaldosteronism)

Type 4 RTA results from decreased aldosterone action leading to hyperkalemia, which in turn impairs ammoniagenesis and reduces net acid excretion. Urine pH is typically below 5.5, indicating intact distal acidification mechanisms, and serum bicarbonate is usually only mildly depressed at 16 to 22 mEq/L. Type 4 RTA is the most common form of RTA in adults. Causes include diabetic nephropathy with hyporeninemic hypoaldosteronism, ACE inhibitors and ARBs, spironolactone and eplerenone, trimethoprim, calcineurin inhibitors, NSAIDs, adrenal insufficiency, and Gordon syndrome. Treatment includes dietary potassium restriction, fludrocortisone 0.1 mg daily, loop diuretics, sodium bicarbonate, and newer potassium binders such as Lokelma or patiromer.

<image>Comparison table of the three types of renal tubular acidosis presented as a clinical reference chart. Columns should include: Type 1 (distal), Type 2 (proximal), and Type 4 (hypoaldosteronism). Rows should show: site of defect, pathophysiology, serum HCO3- range, serum K+ level, urine pH, urine anion gap, nephrocalcinosis/stones risk, associated features, common etiologies (autoimmune, drugs, genetic), and treatment. Use color-coding to highlight key distinguishing features: hypokalemia for Types 1 and 2, hyperkalemia for Type 4; high urine pH for Type 1, low urine pH for Types 2 and 4.</image>

Special Considerations

Dilutional Acidosis

Large-volume normal saline infusion produces a mild non-anion gap metabolic acidosis through the Stewart mechanism: the strong ion difference decreases as chloride rises disproportionately to sodium, shifting the equilibrium toward hydrogen ion generation. This is typically mild and self-limited and can be avoided by using balanced crystalloids.

Post-Hypocapnic Metabolic Acidosis

In patients with chronic respiratory alkalosis, the kidneys compensate by excreting bicarbonate over days. If ventilation is then normalized rapidly, as may occur with mechanical ventilation changes, the serum bicarbonate remains low, producing a non-anion gap metabolic acidosis until the kidneys regenerate the lost bicarbonate.

Recovery Phase of DKA

During treatment of DKA, ketoanions that are metabolized to bicarbonate provide a source of bicarbonate regeneration. However, if ketoanions were excreted renally during the acidotic phase, that potential bicarbonate regeneration is lost, and a non-anion gap metabolic acidosis replaces the original anion gap acidosis. Normal saline resuscitation contributes additional hyperchloremic acidosis, and transitioning to balanced crystalloids during DKA management reduces this iatrogenic component.

Key Clinical Pearls

• Always calculate the albumin-corrected anion gap; failure to do so is the most common error in acid-base interpretation
• The delta-delta ratio reveals hidden disorders: a ratio <1 with elevated AG indicates concurrent non-AG metabolic acidosis; a ratio >2 indicates concurrent metabolic alkalosis
• Urine anion gap is a rapid bedside test to differentiate GI from renal causes of non-AG metabolic acidosis; a negative UAG points to diarrhea, a positive UAG points to RTA
• SGLT2 inhibitor-associated euglycemic DKA is an increasingly recognized entity; maintain high suspicion in patients on SGLT2 inhibitors presenting with AG metabolic acidosis and modest glucose elevations
• In type 2 (proximal) RTA, aggressive alkali therapy worsens hypokalemia because delivered HCO3- exceeds the reabsorptive threshold and acts as a non-reabsorbable anion in the distal nephron, driving K+ secretion

References

1. Kraut JA, Madias NE. Differential Diagnosis of Nongap Metabolic Acidosis: Value of a Systematic Approach. Clin J Am Soc Nephrol. 2012;7(4):671-679.
2. Mehta AN, Emmett JB, Emmett M. GOLD MARK: An Anion Gap Mnemonic for the 21st Century. Lancet. 2008;372(9642):892.
3. Rodriguez Soriano J. Renal Tubular Acidosis: The Clinical Entity. J Am Soc Nephrol. 2002;13(8):2160-2170.
4. Raphael KL, Wei G, Baird BC, et al. Higher serum bicarbonate levels within the normal range are associated with better survival and renal outcomes in African Americans. Kidney Int. 2011;79(3):356-362.
5. Palmer BF, Clegg DJ. Electrolyte Disturbances in Patients with Chronic Alcohol-Use Disorder. N Engl J Med. 2017;377(14):1368-1377.

Read this lecture as Markdown